Determinants of lipid lowering therapy intensification in very high risk patients with dyslipidaemia eligible for PCSK9 monoclonal antibodies: 1-year outcomes of the PERI-DYS study

DSpace Repository

Determinants of lipid lowering therapy intensification in very high risk patients with dyslipidaemia eligible for PCSK9 monoclonal antibodies: 1-year outcomes of the PERI-DYS study

Author: Parhofer, Klaus G.; Pittrow, David; Birkenfeld, Andreas L.; Fraass, Uwe; Hohenstein, Bernd; Siegert, Carsten; Klotsche, Jens; Steinhagen-Thiessen, Elisabeth; Dexl, Stefan; Schettler, Volker J. J.; Laufs, Ulrich
Tübinger Autor(en):
Birkenfeld, Andreas L.
Published in: Acta Cardiologica (2025), Bd. 80, H. 5, S. 475-486
Verlagsangabe: Abingdon : Taylor & Francis Ltd
Language: English
Full text: http://dx.doi.org/10.1080/00015385.2025.2490381
ISSN: 0001-5385
DDC Classifikation: 610 - Medicine and health
Dokumentart: Article
Show full item record

This item appears in the following Collection(s)